Who are Long acting FSH and GnRH antagonist's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/long-acting-fsh-and-gnrh-antagonist.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Long acting FSH and GnRH antagonist — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long acting FSH and GnRH antagonist (Long acting FSH and GnRH antagonist) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH antagonist / FSH receptor agonist combination. Area: Reproductive Endocrinology / Fertility.

marketed GnRH antagonist / FSH receptor agonist combination GnRH receptor, FSH receptor Reproductive Endocrinology / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Long acting FSH and GnRH antagonist (Long acting FSH and GnRH antagonist) — Bioroma. This drug combines long-acting FSH (follicle-stimulating hormone) activity with GnRH antagonism to modulate reproductive hormone signaling for extended periods.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Long acting FSH and GnRH antagonist TARGET	Long acting FSH and GnRH antagonist	Bioroma	marketed	GnRH antagonist / FSH receptor agonist combination	GnRH receptor, FSH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GnRH antagonist / FSH receptor agonist combination class)

Bioroma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Long acting FSH and GnRH antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/long-acting-fsh-and-gnrh-antagonist. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab